

# Dextrose saline versus saline solution infused for the initial rehydration of hyperemesis gravidarum

<b>Submission date</b> 26/04/2012	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 16/05/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 30/11/2015	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Hyperemesis gravidarum (HG) is severe nausea and vomiting occurring during pregnancy. It is fairly common, affecting about 2% of pregnant women, and hospital admission is needed for treatment. HG can lead to dehydration and starvation. The main treatment for HG is intravenous rehydration (fluids given directly into a vein through a drip). It is not known which fluid is best for the initial treatment of HG. Normal saline solution contains salt in the same concentration as blood. Dextrose-saline solution in addition to salt also contains dextrose (a form of sugar). Dextrose will provide calories at a time when the patient is not likely to be drinking or eating properly yet due to HG, which may allow a quicker recovery from starvation. The amount of glucose that we intend to administer over the 24-hour study period is probably about half of the carbohydrate intake in an average woman's diet when she is eating normally. We are investigating whether the addition of dextrose to the intravenous solution used to treat women at the point of their hospitalisation for HG will result in a quicker recovery from starvation and make the patient feel better faster.

### Who can take part?

Women aged 18 and over, hospitalised for the first time in their current pregnancy due to uncomplicated HG, and no more than 16 weeks pregnant.

### What does the study involve?

Participants are randomly allocated to receive either normal saline solution or dextrose-saline solution.

### What are the possible benefits and risks of participating?

In HG patients with severe thiamine deficiency (which can occur after prolonged starvation), dextrose infusion can cause a condition called Wernicke's encephalopathy. To prevent this, before starting rehydration, all participants will receive a multivitamin intravenous injection containing thiamine.

Where is the study run from?  
University Malaya Medical Centre, Kuala Lumpur, Malaysia.

When is the study starting and how long is it expected to run for?  
November 2010 to February 2012.

Who is funding the study?  
University Malaya Medical Centre, Kuala Lumpur, Malaysia.

Who is the main contact?  
Prof P C Tan

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Peng Chiong Tan

**Contact details**  
University of Malaya  
Department of Obstetrics and Gynaecology  
Faculty of Medicine  
Lembah Pantai  
Kuala Lumpur  
Malaysia  
50603

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
811.8

## Study information

**Scientific Title**  
Dextrose saline versus saline solution infused for the initial rehydration of hyperemesis gravidarum: a randomized trial

**Acronym**  
DexSal Trial

**Study objectives**

Rehydration with the intravenous infusion of 5% dextrose-0.9% saline is hypothesised to result in a quicker resolution of ketonuria and generate a higher level of perceived well being compared to 0.9% saline.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

University Malaya Medical Centre Ethics Committee, 22/09/2010, ref: 811.8

### **Study design**

Double-blind randomised intervention trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Hyperemesis gravidarum

### **Interventions**

Three litres of 5% dextrose-0.9% saline or three litres of 0.9% saline solution infused intravenously over 24 hours.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

5% dextrose, 0.9% saline

### **Primary outcome measure**

1. Resolution of ketonuria at 24 hours (using urine dipstick)
2. Well being at 24 hours using a Visual Numerical Rating scale (VNRS)

### **Secondary outcome measures**

1. Correction of hyponatraemia ( $\geq 136$  mmol/l)
2. Correction of hypochloraemia ( $\geq 100$  mmol/l)
3. Hyperglycaemia (any glucose level  $\geq 8$  mmol/l)
4. Nausea score at enrollment, 8, 16 and 24 hours (using VNRS)
5. Duration of intravenous (i.v.) rehydration during hospitalisation
6. Doses of i.v. anti-emetic
7. Admission to discharge interval

**Overall study start date**

09/11/2010

**Completion date**

09/02/2012

## Eligibility

**Key inclusion criteria**

1. Clinical hyperemesis gravidarum with dehydration
2. Age  $\geq 18$  years
3. Pregnancy less than 16 weeks of gestation
4. A positive urine pregnancy test if pregnancy not confirmed by ultrasound
5. Urine ketone at least 1+ on admission
6. First admission for hyperemesis gravidarum in current pregnancy
7. Venous plasma glucose  $\leq 6$  mmol/l
8. Venous sodium  $\geq 125$  mmol/l

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Female

**Target number of participants**

At least 200 women

**Key exclusion criteria**

1. Molar pregnancy
2. Women with underlying medical problem eg established gestational hypertension, diabetes, heart disease, renal disease, thyroid disorder
3. Suspected gastrointestinal causes of nausea and vomiting e.g. gastritis, gastroenteritis, peptic ulcer
4. Established non viable pregnancy
5. Preexisting medical condition that can cause or exacerbate nausea and vomiting (eg culture proven symptomatic urinary tract infection, dengue fever)

**Date of first enrolment**

09/11/2010

**Date of final enrolment**

09/02/2012

## **Locations**

**Countries of recruitment**

Malaysia

**Study participating centre**

**University of Malaya**

Kuala Lumpur

Malaysia

50603

## **Sponsor information**

**Organisation**

University of Malaya (Malyasia)

**Sponsor details**

Department of Obstetrics and Gynaecology

Faculty of Medicine

Lembah Pantai

Kuala Lumpur

Malaysia

50603

**Sponsor type**

University/education

**Website**

<http://www.um.edu.my/>

**ROR**

<https://ror.org/00rzspn62>

## **Funder(s)**

**Funder type**

University/education

**Funder Name**

Department of Obstetrics and Gynaecology, University of Malaya (Malaysia)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/02/2013		Yes	No